The African-PREDICT Study (PREDICT)
African Prospective Study for the Early Detection and Identification of Cardiovascular Disease and Hypertension (African-PREDICT Study)
Sponsor: Boehringer Ingelheim
Listed as NCT03292094, this observational or N/A phase trial focuses on Arterial Stiffness and Cardiovascular Diseases and remains ongoing. Sponsored by Boehringer Ingelheim, it has been updated 15 times since 2013, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting
-
Nov 2022 — May 2024 [monthly]
Active Not Recruiting
▶ Show 10 earlier versions
-
Jul 2022 — Nov 2022 [monthly]
Active Not Recruiting
-
Dec 2021 — Jul 2022 [monthly]
Active Not Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting
-
Sep 2019 — Oct 2020 [monthly]
Active Not Recruiting
-
Sep 2018 — Sep 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- GlaxoSmithKline
- Medical Research Council
- Medical Research Council, South Africa
- Mediclinic Hospital
- National Research Foundation of South Africa
- North-West University, South Africa
- Novartis
- Pfizer
- Roche Diagnostics GmbH
For direct contact, visit the study record on ClinicalTrials.gov .